BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 81 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,826 | -41.8% | 5,166 | +2.4% | 0.00% | – |
| Q2 2023 | $25,482 | +2.3% | 5,046 | -61.7% | 0.00% | – |
| Q1 2023 | $24,920 | -91.1% | 13,185 | -91.5% | 0.00% | -100.0% |
| Q4 2022 | $279,394 | +3.5% | 155,219 | -2.7% | 0.00% | 0.0% |
| Q3 2022 | $270,000 | -31.1% | 159,548 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $392,000 | -86.3% | 159,548 | -84.6% | 0.00% | -83.3% |
| Q1 2022 | $2,867,000 | -48.0% | 1,035,135 | 0.0% | 0.01% | -40.0% |
| Q4 2021 | $5,517,000 | -37.0% | 1,035,135 | 0.0% | 0.01% | -41.2% |
| Q3 2021 | $8,758,000 | -18.0% | 1,035,135 | +18.2% | 0.02% | -15.0% |
| Q2 2021 | $10,678,000 | -49.8% | 875,952 | 0.0% | 0.02% | -51.2% |
| Q1 2021 | $21,251,000 | +10.5% | 875,952 | +46.0% | 0.04% | +5.1% |
| Q4 2020 | $19,230,000 | +34.0% | 600,000 | +26.4% | 0.04% | +14.7% |
| Q3 2020 | $14,351,000 | -28.3% | 474,727 | 0.0% | 0.03% | -32.0% |
| Q2 2020 | $20,014,000 | +100.5% | 474,727 | +18.7% | 0.05% | +72.4% |
| Q1 2020 | $9,980,000 | – | 400,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $104,289,000 | 4.42% |
| Boxer Capital, LLC | 2,014,858 | $60,909,000 | 2.10% |
| RA Capital Management | 2,589,904 | $78,293,000 | 1.43% |
| Artal Group S.A. | 1,521,517 | $45,995,000 | 1.12% |
| Ikarian Capital, LLC | 358,941 | $10,851,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 802,511 | $24,260,000 | 0.59% |
| Bellevue Group AG | 1,403,000 | $42,413,000 | 0.59% |
| Logos Global Management LP | 123,465 | $3,732,000 | 0.48% |
| Casdin Capital, LLC | 289,395 | $8,748,000 | 0.39% |
| HighVista Strategies LLC | 16,391 | $496,000 | 0.36% |